Joan A. Caylà

Dr. Joan A. Caylà

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OGOlga Gil
Olga Gil
IDIvan Díaz
Ivan Díaz
CVCris Vilaplana
Cris Vilaplana
GTGustavo Tapia
Gustavo Tapia
JDJorge Díaz
Jorge Díaz
Pere-Joan CardonaPere-Joan Cardona
Pere-Joan Cardona
A transthoracic infection involving a low dose of Mycobacterium tuberculosis has been used to establish a new model of infection in minipigs. The 20-week monitoring period showed a marked Th1 response and poor humoral response for the whole infection. A detailed histopathological analysis was performed after slicing the formalin-fixed whole lungs of each animal. All lesions were recorded and classified according to their microscopic aspect, their relationship with the intralobular connective network and their degree of maturity in order to obtain a dissemination ratio (DR) between recent and old lesions. CFU counts and evolution of the DR with time showed that the proposed model correlated with a contained infection, decreasing from week 9 onwards. These findings suggest that the infection induces an initial Th1 response, which is followed by local fibrosis and encapsulation of the granulomas, thereby decreasing the onset of new lesions. Two therapeutic strategies were applied in order to understand how they could influence the model. Thus, chemotherapy with isoniazid alone helped to decrease the total number of lesions, despite the increase in DR after week 9, with similar kinetics to those of the control group, whereas addition of a therapeutic M. tuberculosis fragment-based vaccine after chemotherapy increased the Th1 and humoral responses, as well as the number of lesions, but decreased the DR. By providing a local pulmonary structure similar to that in humans, the mini-pig model highlights new aspects that could be key to a better understanding tuberculosis infection control in humans.

8 May 2012 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
JMJoan-Pau Millet
Joan-Pau Millet
AMAntonio Moreno
Antonio Moreno
LFLaia Fina
Laia Fina
LBLucía del Baño
Lucía del Baño
AOAngels Orcau
Angels Orcau
JCJoan A. Caylà
Joan A. Caylà

1 April 2017 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
MRMorten Ruhwald
Morten Ruhwald
HAHenrik Aggerbeck
Henrik Aggerbeck
RGRafael Vázquez Gallardo
Rafael Vázquez Gallardo
SHSøren T Hoff
Søren T Hoff
JVJosé I Villate
José I Villate
JCJoan A. Caylà
Joan A. Caylà

1 October 2008 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
JRJuan Ruiz-Manzano
Juan Ruiz-Manzano
RBRafael Blanquer
Rafael Blanquer
JCJosé Luis Calpe
José Luis Calpe
JCJosé A. Caminero
José A. Caminero
JCJoan A. Caylà
Joan A. Caylà
RVRafael Vidal
Rafael Vidal

11 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJoan-Pau Millet
Joan-Pau Millet
ESEvelyn Shaw
Evelyn Shaw
ÀOÀngels Orcau
Àngels Orcau
MCMartí Casals
Martí Casals
JMJose M. Miró
Jose M. Miró
TGThe Barcelona Tuberculosis Recurrence Working Group
The Barcelona Tuberculosis Recurrence Working Group
Tuberculosis (TB) recurrence can be due to reinfection or relapse. The contribution of each to TB incidence and the factors associated with recurrence are not well known. Effectiveness of TB control programs is assessed in part by recurrence rates. The aim of this study was to establish the recurrence rate of TB in Barcelona, the associated risk factors and the role of reinfection. A population-based retrospective longitudinal study was performed in Barcelona, Spain. TB patients with positive culture results who completed treatment between Jan 1st, 2003 and Dec 31st, 2006 were followed-up until December 31st, 2009 by the TB Control Program. The incidence rate of recurrence was calculated per person-year of follow-up (py). Kaplan-Meier and Cox regression methods were used for the survival analysis by calculating the hazard ratio (HR) with 95% confidence intervals (CI). Of the 1,823 TB cases identified, 971 fulfilled the inclusion criteria and 13 (1.3%) had recurrent TB. The recurrence rate was 341 cases per 100,000 py, 13 times higher than the TB incidence of the general population. Likelihood of TB recurrence at the 1st, 3rd and 5th year of follow-up was 0.1%, 1.4% and 1.6%, respectively. Factors associated with recurrence were HIV infection (HR: 4.7, CI: 1.4–15.7), living in the inner city district (HR: 3.9, CI: 1.3–11.8) and history of TB treatment (HR: 5.2, CI: 1.7–16.2). Genotyping results of recurrent cases were available for 6 patients (3 reinfections and 3 relapses). The rate of TB recurrence in Barcelona is low and most episodes occur within the first three years. Patients at higher risk of recurrence are co-infected with HIV, living in neighborhoods with high TB incidence or with a history of TB treatment. When available, genotyping results help determine whether the recurrence is due to reinfection or relapse.

18 October 2006 in European Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
CBCarme Borrell
Carme Borrell
MMMarc Marí-Dell’olmo
Marc Marí-Dell’olmo
MRMaica Rodríguez-Sanz
Maica Rodríguez-Sanz
PGPatrícia Garcia-Olalla
Patrícia Garcia-Olalla
JCJoan A. Caylà
Joan A. Caylà
CMCarles Muntaner
Carles Muntaner